Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

February 26, 2024

Study Completion Date

March 18, 2024

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

PLN-74809

PLN-74809

DRUG

Placebo

Placebo

Trial Locations (60)

1070

Department Gastroenterology, Hepatopancreatology and Digestive Oncology CUB Hôpital Erasme, Brussels

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Westmead

2170

Liverpool Hospital: Department of Gastroenterology and Hepatology, Liverpool

2650

Universitair Ziekenhuis Antwerpen, Edegem

3000

UZ Leuven, Leuven

3004

The Alfred, Melbourne

3065

St. Vincent's Hospital, Melbourne

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

8036

Medizinische Universität Graz, Graz

9000

Ghent University Hospital, Ghent

13353

Charité University Medicine Berlin, Berlin

19104

Perelman Center for Advanced Medicine, Philadelphia

20246

University Medical Center Hamburg -Eppendorf/ I. Dept of Medicine, Hamburg

23298

VCU Health Clinical Research Services Unit, Richmond

23602

Bon Secours Liver Institute of Hampton Roads, Newport News

27710

Duke University Medical Center, Durham

30309

Piedmont Atlanta Hospital, Atlanta

33136

Schiff Center of Liver Diseases/University of Miami, Miami

34211

Florida Research Institute, Lakewood Rch

37232

Vanderbilt Digestive Disease Center, Nashville

46202

Indiana University Health University Hospital, Indianapolis

48109

University of Michigan, Ann Arbor

48377

Henry Ford Health System, Novi

55131

Universitätsmedizin Mainz, I. Med. Klinik, Mainz

59037

CHU de Lille service MAD, Lille

60637

University of Chicago Medical Center, Chicago

67200

C.H.U. Hautepierre, Strasbourg

69120

University Hospital Heidelberg, Heidelberg

75012

Saint Antoine Hospital/ Hepatology Department, Paris

77030

Baylor College of Medicine - Advanced Liver Therapies, Houston

91054

University Hospital Erlangen, Erlangen

91105

California Liver Research Institute, Pasadena

94063

Stanford University School of Medicine, Redwood City

94109

California Pacific Medical Center Research Institute, San Francisco

94143

University of California San Francisco, San Francisco

94800

Centre Hépato-Biliaire - Hôpital Paul-Brousse, Villejuif

95817

University of California, Davis Medical Center, Sacramento

98105

Liver Institute Northwest, Seattle

06511

Yale School of Medicine, New Haven

02114

Massachusetts General Hospital Gastroenterology Liver Center, Boston

A-1090

Medical University of Vienna Div. of Gastroenterology and Hepatology, Vienna

T3H 0V5

Aspen Woods Clinic, Calgary

T6G 2X8

University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre, Edmonton

V6Z 2K5

(G.I.R.I) GI Research Institute, Vancouver

L8N 3Z5

McMaster University Medical Centre, Hamilton

N6A 5A5

London Health Sciences Centre-University Hospital, London

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 2C4

Toronto Centre for Liver Disease (TCLD), University Health Network, Toronto General Hospital, Toronto

H2X 0A9

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal

H4A3J1

McGill University Health Centre, Montreal

38043 CEDEX 9

CHU Grenoble Alpes - Hôpital Michallon, Grenoble

1105 AZ

Amsterdam UMC, Amsterdam

2333 ZA

Leiden University Medical Center, Leiden

3015 GD

Erasmus University Medical Center, Rotterdam

NR4 7UY

Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich

OX3 9DU

John Radcliffe Hospital/Oxford University Hospital, Headington

B15 2GW

University Hospitals Birmingham NHS, Birmingham

SE5 9RS

King's College Hospital NHS Foundation Trust, Denmark Hill, London

Sponsors
All Listed Sponsors
lead

Pliant Therapeutics, Inc.

INDUSTRY

NCT04480840 - Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) | Biotech Hunter | Biotech Hunter